News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TYRX Completes Study Site Enrollment in CITADEL & CENTURION Clinical Studies Utilizing AIGISRx® Antibacterial Envelope During ICD/CRT Replacements


10/28/2010 11:45:23 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiac implantable electronic devices (CIEDs), announced today that it has completed the site enrollment phase of its 50-site CITADEL & CENTURION studies to evaluate the company’s AIGISRx Antibacterial Envelope.

Read at BioSpace.com


comments powered by Disqus
TYRX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES